# Advisor Review - Gemini-3-Flash

**Role:** Academic advisor checking for fatal errors
**Model:** gemini-3-flash-preview (ai_studio)
**Paper:** paper.pdf
**Timestamp:** 2026-03-09T11:01:46.178289
**Route:** Direct Google API + PDF
**Paper Hash:** cdf9a1c4c9932124
**Tokens:** 19878 in / 748 out
**Response SHA256:** 9321ef473f188e10

---

I have reviewed the draft paper "Selective Licensing and Housing Markets in England: Staggered Adoption, TWFE Bias, and Null Effects." My review follows the specific criteria for catching fatal errors.

### 1. DATA-DESIGN ALIGNMENT
*   **Treatment timing vs. data coverage:** The paper claims to study the rollout of selective licensing through 2024. The data section (4.1) and Appendix (A.1) state that HM Land Registry annual files for **2005–2024** were used. Figure 1 and Section 2.2 explicitly list 2024 cohorts (e.g., Westminster). Because the data extends to the end of the treatment adoption period, this alignment is correct.
*   **Post-treatment observations:** For the latest cohort (2024), the paper acknowledges in Section 8.6 that there is "at most one year of post-treatment data." While thin, it satisfies the requirement for post-treatment observations.
*   **Consistency:** Table 1 and Figure 1 note $N=52$ treated local authorities, which matches the description in the text.

### 2. REGRESSION SANITY
*   **Standard Errors:** Table 2, Column 1 shows a coefficient of $0.0386$ with an SE of $0.0192$. This is a typical, sane result for log price outcomes.
*   **Coefficients:**
    *   Table 2 coefficients are all $< 0.1$, which is standard for log property price studies.
    *   **Potential Concern:** In Section 6.4 (and Table 5), the "Continuous dose" model reports a coefficient for the interaction term $\beta_2 = +0.96$. While large, the text explains this is for a proportion (0 to 1). A 10 percentage point increase in PRS share leads to a $0.096$ change in log price, which is plausible and does not meet the "Fatal" threshold of $> 100$.
*   **Impossible Values:** R-squared values are not explicitly listed in Table 2, but the sample sizes (N) and coefficients are consistent. No "NaN", "Inf", or negative SEs were found.

### 3. COMPLETENESS
*   **Placeholder values:** I scanned the text and tables for "TBD", "PLACEHOLDER", or "XXX". None were found.
*   **Missing elements:** Table 2 includes Observation counts ($N$). Standard errors are provided in parentheses.
*   **Incomplete analyses:** The dose-response model mentioned in Section 6.4 is supported by a summary of results in Table 5 (Appendix D.1).

### 4. INTERNAL CONSISTENCY
*   **Numbers match:** The abstract cites a TWFE estimate of 3.9% ($p=0.045$). Table 2, Column 1 shows $0.0386$ ($p=0.044$). These are consistent. The CS-DiD estimate of -3.5% cited in the abstract matches Table 2, Column 3 ($-0.0353$).
*   **Timing consistency:** Adoption spans 2008–2024 throughout the text, figures, and tables.
*   **Sample period:** All primary analyses use the 2005–2024 sample window.

**ADVISOR VERDICT: PASS**